Last reviewed · How we verify
Rivastigmine prevention of delirium
Rivastigmine prevention of delirium is a Cholinesterase inhibitor Small molecule drug developed by University Hospital, Basel, Switzerland. It is currently in Phase 3 development for Prevention of delirium.
Rivastigmine is a cholinesterase inhibitor that works by increasing the concentration of acetylcholine in the brain, which helps to improve cognitive function and prevent delirium.
Rivastigmine is a cholinesterase inhibitor that works by increasing the concentration of acetylcholine in the brain, which helps to improve cognitive function and prevent delirium. Used for Prevention of delirium.
At a glance
| Generic name | Rivastigmine prevention of delirium |
|---|---|
| Sponsor | University Hospital, Basel, Switzerland |
| Drug class | Cholinesterase inhibitor |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the enzyme acetylcholinesterase, rivastigmine allows acetylcholine to accumulate in the brain, stimulating cholinergic receptors and enhancing neurotransmission. This mechanism is thought to be beneficial in the treatment of Alzheimer's disease and other neurodegenerative disorders, including delirium prevention.
Approved indications
- Prevention of delirium
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Headache
Key clinical trials
- Rivastigmine Patch Compared to Melatonin Patch in Prevention of Postoperative Delirium (PHASE1, PHASE2)
- Rivastigmine for the Prevention of Postoperative Delirium in Patients Undergoing Cardiac Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rivastigmine prevention of delirium CI brief — competitive landscape report
- Rivastigmine prevention of delirium updates RSS · CI watch RSS
- University Hospital, Basel, Switzerland portfolio CI
Frequently asked questions about Rivastigmine prevention of delirium
What is Rivastigmine prevention of delirium?
How does Rivastigmine prevention of delirium work?
What is Rivastigmine prevention of delirium used for?
Who makes Rivastigmine prevention of delirium?
What drug class is Rivastigmine prevention of delirium in?
What development phase is Rivastigmine prevention of delirium in?
What are the side effects of Rivastigmine prevention of delirium?
What does Rivastigmine prevention of delirium target?
Related
- Drug class: All Cholinesterase inhibitor drugs
- Target: All drugs targeting Acetylcholinesterase
- Manufacturer: University Hospital, Basel, Switzerland — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Prevention of delirium
- Compare: Rivastigmine prevention of delirium vs similar drugs
- Pricing: Rivastigmine prevention of delirium cost, discount & access